Clinical effect and safety of nutritional support after pancreaticoduodenectomy: A Meta-analysis

Zhang BaoHua; Yang Ya; Gong JianPing

doi:10.3969/j.issn.1001-5256.2018.06.020

Issue 6

Jun. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(6): 1231-1236

PDF( 2074 KB)

Clinical effect and safety of nutritional support after pancreaticoduodenectomy: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2018.06.020

Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Hepatobiliary Surgery

Received Date: 2017-11-02
Published Date: 2018-06-20

Abstract

Abstract

Objective To investigate the effect of different nutritional support methods (including total parenteral nutrition, early oral nutrition, early enteral nutrition via nasojejunal tube, early enteral nutrition via gastric fistula, and early enteral nutrition via jejunal fistula) on the prognosis of patients after pancreaticoduodenectomy (PD) . Methods Pub Med, Embase, and The Cochrane Library were searched for articles on nutritional support after PD published from 2007 to 2017. A pooled analysis was performed for related data including sample size, research contents, study population, research roadmap and methods, length of hospital stay, and incidence rates of infection (including postoperative pulmonary infection and incision infection) , pancreatic fistula (grade B/C) , and delayed gastric emptying, and Rev Man 5. 3 software was used for the meta-analysis of total parenteral nutrition and early enteral nutrition via nasojejunal tube after PD. Results A total of 11 articles were included, and 4 were included in the meta-analysis. The horizontal comparison showed no significant difference in the length of hospital stay between the patients undergoing nutritional support via different pathways, while the vertical comparison showed a significant difference. As for complications, the gastric fistula group had a significantly higher incidence rate of pancreatic fistula than the other groups (all P < 0. 01) , and the jejunal fistula group had a significantly higher incidence rate of delayed gastric emptying than the other groups (all P < 0. 01) . The total parenteral nutrition group had an incidence rate of infection of 27. 17%, which was lower than that in the other groups (40. 63% 、46. 58% 、33. 64%) , but there was no statistical significance in the differences (all P > 0. 05) . The meta-analysis showed no significant differences between the total parenteral nutrition group and the nasojejunal tube early enteral nutrition group in length of hospital stay, delayed gastric emptying, and incidence rates of pancreatic fistula and infection. Conclusion Nutritional strategies after PD have similar clinical effects and safety, and a reasonable nutritional support regimen can be developed based on clinical practice and patients' conditions.
- pancreaticoduodenectomy,
- nutritional support,
- Meta-analysis

FullText(HTML)

References(22)

References

[1]MARIN FA, LAMONICA VC, HENRY MA, et al.Grade of esophageal cancer and nutritional status impact on postsurgery outcomes[J].Arq Gastroenterol, 2010, 47 (4) :348-353.

[2]DONG K, YU XJ, LI B, et al.Advances in mechanisms of postsurgical gastroparesis syndrome and its diagnosis and treatment[J].Chin J Dig Dis, 2006, 7 (2) :76-82.

[3]CORREIA MI, WAITZBERG DL.The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis[J].Clin Nutr, 2003, 22 (3) :235-239.

[4]MAZAKI T, EBISAWA K.Enteral versus parenteral nutrition after gastrointestinal surgery:A systematic review and metaanalysis of randomized controlled trials in the English literature[J].Gastrointest Surg, 2008, 12 (4) :739-755.

[5]GERRITSEN A, BESSELINK MGH, GOUMA DJ, et al.Systematic review of five feeding routes after Pancreatoduodenectomy[J].Br J Surg, 2013, 100 (5) :589-598.

[6]MOHER D, LIBERATI A, TETZLAFF J, et al (PRISMA Group) .Preferred reporting items for systematic reviews and meta-analyses:The PRISMA statement[J].Ann Intern Med, 2009, 151 (62) :264-269.

[7]CEBM.Oxford Centre for Evidence-Based Medicine Levels of Evidence Working Group[EB/OL].OCEBM Levels of Evidence, 2011.http://www.cebm.net/index.aspx?o=5653.

[8]WENTE MN, BASSI C, DERVENIS C, et al.Delayed gastric emptying (DGE) after pancreatic surgery:A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS) [J].Surgery, 2007, 142 (5) :761-768.

[9]BASSI C, DERVENIS C, BUTTURINI G, et al.Postoperative pancreatic fistula:An international study group (ISGPF) definition[J].Surgery, 2005, 138 (1) :8-13.

[10]BERBERAT PO, INGOLD H, GULBINAS A, et al.Fast track-different implications in pancreatic surgery[J].Gastrointest Surg, 2007, 11 (7) :880-887.

[11]RAYS N, SEEHOFER D, THERUVATH T, et al.Effect of enteral nutrition and synbiotics on bacterial infection rates after pyloruspreserving pancreatoduodenectomy:A randomized, double-blind trial[J].Ann Surg, 2007, 246 (1) :36-41.

[12]BALZANO G, ZERBI A, BRAGA M, et al.Fast-track recovery programme after pancreaticoduodenectomy reduces delayed gastric emptying[J].Br J Surg, 2008, 95 (11) :1387-1393.

[13]HALLAY J, MICSKER C, FULESDI B, et al.Use of three lumen catheter facilitates bowelmovement after pancreato-duodenectomy[J].Hepatogastroenterology, 2008, 55 (84) :1099-1102.

[14]YERMILOV I, JAIN S, SEKERIS E, et al.Utilization of parenteral nutrition following pancreaticoduodenectomy:Is routine jejunostomy tube placement warranted?[J].Dig Dis Sci, 2009, 54 (7) :1582-1588.

[15]ABU-HILAL M, HEMANDAS AK, Mc PHAIL M, et al.A comparative analysis of safety and efficacy of different methods of tube placement for enteral feeding following major pancreatic resection.A non-randomized study[J].JOP, 2010, 11 (1) :8-13.

[16]GERRITSEN A, BESSELINK MG, CIESLAK KP, et al.Efficacy and complications of nasojejunal, jejunostomy and parenteral feeding after pancreaticoduodenectomy[J].J Gastrointest Surg, 2012, 16 (6) :1144-1151.

[17]PARK JS, CHUNG HK, HWANG HK, et al.Postoperative nutritional effects of early enteral feeding compared with total parental nutrition in pancreaticoduodectomy patients:A prosepective, randomized study[J].Korean Med Sci, 2012, 27 (3) :261-267.

[18]ZHU XH, WU YF, QIU DY, et al.Effect of early enteral combined with parenteral nutrition in patients undergoing pancreaticoduodenectomy[J].World J Gastroenterol, 2013, 19 (35) :5889-5896.

[19]LU JW, LIU C, DU ZQ, et al.Early enteral nutrition vs parenteral nutrition following pancreaticoduodenectomy:Experience from a single center[J].World J Gastroenterol, 2016, 22 (14) :3821-3828.

[20]GUILBAUD T, BIRNBAUM DJ, LOUBIRE S, et al.Comparison of different feeding regimes after pancreatoduodenectomy-a retrospective cohort analysis[J].Nutr J, 2017, 16 (1) :42.

[21]BRAUNSCHWEIG CL, LEVY P, SHEEAN PM, et al.Enteral compared with parenteral nutrition:A meta-analysis[J].Am J Clin Nutr, 2001, 74 (4) :534-542.

[22]MAHADEVA S, MALIK A, HILMI I, et al.Transnasal endoscopic placement of nasoenteric feeding tubes:Outcomes and limitations in non-critically ill patients[J].Nutr Clin Pract, 2008, 23 (2) :176-181.

Relative Articles

[1]	Linhui HU, Yan WANG. Clinical controversies over antiviral therapy for patients in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2024, 40(5): 875-879. doi: 10.12449/JCH240505
[2]	Yanlin LI, Yan WANG, Yingqiong ZHOU, Xueliang YANG, Na CHEN, Fangyao CHEN, Xiaojing LIU. Antiviral therapy for patients with chronic hepatitis B in the immune-tolerant phase: A systematic review[J]. Journal of Clinical Hepatology, 2021, 37(6): 1282-1287. doi: 10.3969/j.issn.1001-5256.2021.06.013
[3]	Fengxia SUN. Dynamic measurement of spleen size and liver stiffness helps to judge whether antiviral therapy is needed in the immune-tolerant phase of HBV infection[J]. Journal of Clinical Hepatology, 2021, 37(5): 1027-1027. doi: 10.3969/j.issn.1001-5256.2021.05.009
[4]	Hongyu JIA, Kezhou LIU. Antiviral therapy for patients in the immune-tolerant phase of chronic HBV infection is beneficial for preventing liver cirrhosis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1024-1025. doi: 10.3969/j.issn.1001-5256.2021.05.007
[5]	Zixin CUI, Jiayun LI, Peiyao WEI, Yunru CHEN, Jianzhou LI, Feng YE. Individualized treatment should be performed in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(6): 1277-1277. doi: 10.3969/j.issn.1001-5256.2021.06.009
[6]	Hui ZHUANG. Should patients in the immune tolerance stage of chronic hepatitis B virus infection be treated?[J]. Journal of Clinical Hepatology, 2021, 37(2): 272-277. doi: 10.3969/j.issn.1001-5256.2021.02.007
[7]	Hui ZHUANG. Correction note on the estimated number of patients in the immune-tolerant phase of hepatitis B virus infection in China and globally[J]. Journal of Clinical Hepatology, 2021, 37(4): 785-786. doi: 10.3969/j.issn.1001-5256.2021.04.012
[8]	Tingting LI, Yanfang JIANG. Patients in the immune-tolerant phase of chronic HBV infection should be precisely treated with antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(5): 1022-1023. doi: 10.3969/j.issn.1001-5256.2021.05.006
[9]	Xinyue CHEN, Aixin SONG. Antiviral therapy should be selected for patients in the immune-tolerant phase of chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(6): 1278-1278. doi: 10.3969/j.issn.1001-5256.2021.06.010
[10]	Bingliang LIN. Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load[J]. Journal of Clinical Hepatology, 2021, 37(4): 778-780. doi: 10.3969/j.issn.1001-5256.2021.04.009
[11]	Aiping WANG, Chunyang WEN. Thoughts on recommendations for immune-tolerant phase of chronic hepatitisB virus infection in Guidelines for the management of hepatitis B (version 3.3) released by the Japan Society of Hepatology[J]. Journal of Clinical Hepatology, 2021, 37(7): 1528-1528. doi: 10.3969/j.issn.1001-5256.2021.07.009
[12]	Min QUAN, Huichun XING. Antiviral therapy is not recommended in immune-tolerant phase chronic hepatitis B patients without complications[J]. Journal of Clinical Hepatology, 2021, 37(6): 1279-1280. doi: 10.3969/j.issn.1001-5256.2021.06.011
[13]	Li XIAO, Jianchun XIAN. Patients in the immune-tolerant phase of chronic hepatitis B can receive antiviral therapy conditionally[J]. Journal of Clinical Hepatology, 2021, 37(4): 781-782. doi: 10.3969/j.issn.1001-5256.2021.04.010
[14]	Yuan HUANG. Patients in the immune-tolerant phase of chronic HBV infection should be actively treated with antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(5): 1026-1026. doi: 10.3969/j.issn.1001-5256.2021.05.008
[15]	Letian LI. Antiviral therapy should be used selectively in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(6): 1275-1276. doi: 10.3969/j.issn.1001-5256.2021.06.008
[16]	Deyang WANG, Jun JIANG, Kekai ZHAO. Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(4): 775-776. doi: 10.3969/j.issn.1001-5256.2021.04.007
[17]	Minghui LI, Yao XIE. Antiviral therapy is not recommended for patients in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(4): 783-784. doi: 10.3969/j.issn.1001-5256.2021.04.011
[18]	Jia SHANG. Active antiviral therapy should be given in the immune tolerance stage of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(4): 777-777. doi: 10.3969/j.issn.1001-5256.2021.04.008
[19]	Zhou LuLu, Liu Na, Li ChunXia, Dong Bing, Bai XiaoXiao, Zhang Nan, Xu GuangHua. Research advances in the diagnosis and treatment of patients in the immune tolerance stage of chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2019, 35(8): 1824-1827. doi: 10.3969/j.issn.1001-5256.2019.08.039
[20]	Wang Kai, Gao Wei. Research advances in immune tolerance in children receiving liver transplantation[J]. Journal of Clinical Hepatology, 2019, 35(11): 2402-2407. doi: 10.3969/j.issn.1001-5256.2019.11.005

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	卓勇佳，叶枫，唐可京，简怡飞，肖敦明，宣建伟. 中国侵袭性曲霉病患者的诊疗情况及经济负担. 中国药物经济学. 2023(01): 27-31+35 .
2.	张聪，戴钱姣，朱潇冉，潘颖璐，戴霞红. 伏立康唑与卡泊芬净治疗肝衰竭并发侵袭性肺感染的效果比较. 中国现代医生. 2021(14): 115-118 .
3.	单明珠，颜鸣菊，朱作斌，陈莹，顾兵，李颖. 2007-2019年肺部真菌感染危险因素与病原菌分布的荟萃分析. 中华医院感染学杂志. 2020(02): 174-179 .
4.	戴婧，祝存奎，孙秀媛. 慢加急性肝衰竭患者侵袭性真菌感染后的临床表现及影响因素分析. 肝脏. 2020(10): 1098-1100 .
5.	卓丽，兰芸，李粤平，陈万山，邓西龙. 实时荧光定量PCR法对肝衰竭合并侵袭性肺曲霉菌病患者的诊断价值. 实用医学杂志. 2019(18): 2946-2949 .
6.	黄锦焕，陈潮钦. 侵袭性肺曲霉菌病的诊断研究进展. 按摩与康复医学. 2017(15): 5-6 .
7.	涂雪松，涂新羽，黄福恩，胡利霞. 肝功能衰竭并发曲霉菌感染者的临床特征及相关性研究. 中华实验和临床感染病杂志(电子版). 2017(06): 591-594 .

Other cited types(5)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1848) PDF downloads(355)

Clinical effect and safety of nutritional support after pancreaticoduodenectomy: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2018.06.020